Similar to antibodies, centyrin conjugates – small, engineered proteins derived from a human protein Tenascin C – have been designed to bind with high affinity and selectivity to numerous antigens, which makes specific tumour targeting across a broad range of tumour antigens feasible. The gene discussed is TNC; the disease is neoplasm.